Key Highlights
- ImmunityBio (IBRX) shares advanced 3% Monday following the submission of a compliance response to the FDA
- FDA regulators identified a television commercial and podcast related to Anktiva as potentially false or misleading in March 2026
- ImmunityBio stated the television commercial was never publicly aired; the podcast has been taken down from its website
- The biotech company is introducing required executive training programs and enhanced review procedures
- Preliminary results from the QUILT-2.005 trial verified the study has sufficient statistical power for a Q4 2026 supplemental FDA submission
ImmunityBio (IBRX) shares rose 3% Monday following the biotech firm’s formal submission to the FDA addressing promotional compliance issues related to Anktiva, its bladder cancer treatment.
The FDA’s Office of Prescription Drug Promotion raised concerns about a television commercial and podcast content in a letter dated March 13, 2026, characterizing both materials as potentially false or misleading.
ImmunityBio contested at least one of the allegations — specifically noting that the television commercial referenced by the FDA never went on air or reached any public audience.
The disputed podcast contained statements from Founder and Executive Chairman Dr. Patrick Soon-Shiong. According to the company, his remarks were intended as forward-looking commentary regarding its drug development programs rather than assertions about currently approved therapeutic uses.
ImmunityBio has pulled the podcast from its official website and has asked third-party platforms hosting the content to remove it as well.
CEO Richard Adcock emphasized that the organization “takes promotional compliance with the utmost seriousness” and highlighted the importance of maintaining clear boundaries between investigational therapies and approved treatment indications.
Regarding remedial measures, the company is rolling out mandatory compliance training for executives, strengthening Promotional Review Committee procedures, and engaging external regulatory advisors to assess future high-profile communications.
Litigation Risk Intensifies
The FDA correspondence has spawned consequences beyond regulatory scrutiny. Several law firms have initiated securities class action lawsuits, claiming investors received misleading information about Anktiva’s therapeutic potential and the company’s promotional conduct.
This represents a significant overhang. Even if the FDA accepts the company’s response, the ongoing litigation creates additional uncertainty for shareholders already monitoring a firm with substantial cash expenditures and reliance on a single commercialized product.
Clinical Progress Provides Balance
Despite regulatory turbulence, Anktiva’s clinical development continues advancing. Preliminary findings from the pivotal QUILT-2.005 trial demonstrated that an independent data monitoring committee validated the 366-patient randomized study — evaluating Anktiva combined with BCG versus BCG monotherapy — has appropriate statistical power for the planned supplemental BLA submission in Q4 2026.
This regulatory submission would seek approval for BCG-naïve non-muscle invasive bladder cancer patients, representing a wider indication than Anktiva’s existing authorization.
Anktiva currently holds approval in combination with Bacillus Calmette-Guérin for adult patients diagnosed with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
Analyst revenue projections show considerable variation. Conservative estimates suggest $1.2 billion in revenue and $435.5 million in earnings by 2029 — necessitating approximately 119% compound annual revenue growth from the current loss position of -$351.4 million.
Optimistic scenarios project revenue reaching $1.6 billion with earnings of $671.9 million by that same timeframe.
The Q4 2026 supplemental BLA submission represents the nearest-term catalyst for investors to monitor.
